#Intra-Cellular Therapies Inc

[classifieds-marketing-news]

Biggest movers before the market opens: Abercrombie & Fitch, Pinterest, Hilton Grand Vacations

Top News in the Stock Market Today Quantum Stocks Plunge After Zuckerberg's Comments Quantum stocks took a hit following remarks from Mark Zuckerberg and Nvidia CEO Jensen Huang, with Rigetti Computing and D-Wave Quantum seeing significant drops. Managed Care Stocks on the Rise Managed care stocks saw gains after the US government proposed a reimbursement rate increase for Medicare Advantage plans, with Humana, UnitedHealth, and CVS Health all rising. Boot Barn Guides Higher Boot retailer Boot Barn's guidance for third-quarter earnings exceeded expectations, leading to a 4% jump in its stock price. Pinterest Slides After Downgrade Pinterest shares dropped after a downgrade from Jefferies, citing underwhelming growth forecasts for the company. Crypto Stocks Decline with Bitcoin Stocks tied to the price of bitcoin fell as the cryptocurrency dipped, affecting companies like Coinbase and MicroStrategy. Lululemon Sees Strong Demand Lululemon reported strong holiday sales, leading to a 3% increase in shares and an upward revision of its sales and earnings guidance. Macy's Issues Lackluster Guidance Macy's shares fell after issuing a disappointing update to its fourth-quarter guidance, with revenue expected to fall below previous estimates. Abercrombie & Fitch Raises Outlook Despite a plunge in premarket trading, Abercrombie & Fitch raised its fourth-quarter sales outlook on strong holiday sales expectations. Howard Hughes Holdings Soar Shares of real estate developer Howard Hughes Holdings jumped 9% after a proposal from Bill Ackman's Pershing Square for a new entity merger. Tech Stocks Tumble as Treasury Yields Rise Megacap tech stocks like Nvidia, Tesla, and Palantir Technologies saw losses as US Treasury yields increased. Moderna Lowers Sales Guidance Biotech firm Moderna saw a 20% drop after lowering its 2025 sales guidance, citing potential headwinds in the coming year. Intra-Cellular Therapies Acquired by Johnson & Johnson Intra-Cellular Therapies' stock surged after an announcement of an acquisition by Johnson & Johnson for $132 per share. Contributing reporting by Michelle Fox, Alex Harring, Yun Li, Tanaya Macheel, Sarah Min, Jesse Pound, and Pia Singh. #Money #Abercrombie #AbercrombieFitchCo #Biggest #BootBarnHoldingsInc #breakingnews #BreakingNewsMarkets #BroadcomInc #Business #businessnews #CoinbaseGlobalInc #CoreScientificInc #CVSHealthCorp #DPCMCapitalInc #economy #Fitch #Grand #Hilton #HumanaInc #IntraCellularTherapiesInc #IONQInc #JohnsonJohnson #LululemonAthleticaInc #MacysInc #MarathonDigitalHoldingsInc #market #MarketInsider #markets #MetaPlatformsInc #MicronTechnologyInc #MicrostrategyInc #ModernaInc #movers #NVIDIACorp #opens #PalantirTechnologiesInc #Pinterest #PinterestInc #QuantumComputingInc #regwallmarketmovers #RigettiComputingInc #Stockmarkets #TeslaInc #UnitedHealthGroupInc #vacations #WD40Co https://tinyurl.com/2anpls3u

[wissenresearchllc]

The global 𝐛𝐢𝐩𝐨𝐥𝐚𝐫 𝐝𝐢𝐬𝐨𝐫𝐝𝐞𝐫 𝐦𝐚𝐫𝐤𝐞𝐭 is estimated to be valued at ~ $4.5 Billion in 2023 and projected to reach ~$5.4 Billion in 2030. The market is expected to grow at a CAGR of ~2-3% during the forecast period 2024-2030. Click to access the 𝐁𝐢𝐩𝐨𝐥𝐚𝐫 𝐃𝐢𝐬𝐨𝐫𝐝𝐞𝐫 𝐌𝐚𝐫𝐤𝐞𝐭 report: https://lnkd.in/g75un3hF 𝐌𝐚𝐣𝐨𝐫 𝐏𝐥𝐚𝐲𝐞𝐫𝐬 • GSK PLC (UK) • ELI LILLY AND COMPANY (US) • ASTRAZENECA (UK) • PFIZER INC. (US) • SANOFI (FRANCE) • JOHNSON & JOHNSON (US) • NOVARTIS AG (SWITZERLAND) • ABBVIE INC. (US) Request customized 𝐁𝐢𝐩𝐨𝐥𝐚𝐫 𝐃𝐢𝐬𝐨𝐫𝐝𝐞𝐫 𝐌𝐚𝐫𝐤𝐞𝐭 report: https://lnkd.in/d6q8Q-5a 𝐒𝐭𝐫𝐚𝐭𝐞𝐠𝐢𝐜 𝐀𝐜𝐭𝐢𝐯𝐢𝐭𝐢𝐞𝐬 • Johnson & Johnson acquired Intra-Cellular Therapies and strengthened leadership in Bipolar Disorder treatment with CAPLYTA®. (Jan 2025) • Hope Therapeutics acquired Kadima Neuropsychiatry Institute to expand its network for advanced treatments for Depression, Anxiety, and PTSD. (Jan 2025) • Lyndra and Thermo Fisher partnered to develop long-acting oral therapies for Schizophrenia and Bipolar Disorder. (Jan 2025) 𝐅𝐨𝐫 𝐦𝐨𝐫𝐞 𝐝𝐞𝐭𝐚𝐢𝐥𝐬 𝐚𝐧𝐝 𝐩𝐞𝐫𝐬𝐨𝐧𝐚𝐥𝐢𝐳𝐞𝐝 𝐢𝐧𝐬𝐢𝐠𝐡𝐭𝐬, 𝐫𝐞𝐚𝐜𝐡 𝐨𝐮𝐭 𝐭𝐨 𝐮𝐬 𝐭𝐨𝐝𝐚𝐲! 𝐂𝐨𝐧𝐭𝐚𝐜𝐭: https://lnkd.in/gMPx_qnY 𝐄𝐦𝐚𝐢𝐥: info@wissenresearch.com

[impact-newswire]

Johnson & Johnson Strengthens Neuroscience Leadership with Acquisition of Intra-Cellular Therapies, Inc.

Acquisition includes CAPLYTA® (lumateperone), the first and only U.S. FDA-approved treatment for bipolar I and II depression as an adjunctive and monotherapy; also approved for the treatment of schizophrenia in adults sNDA submitted to U.S. FDA for CAPLYTA® as adjunctive treatment for major depressive disorder; if approved, CAPLYTA® has potential to become a standard of care for most common…

[fmarkets]

Intra-Cellular Therapies Inc. Sees Record Revenue Surge, Leading to Deficit Reduction $ITCI #Stockmarket #Nasdaq

Navigating Uncertainties: The Financial Journey of Intra-Cellular Therapies Inc.Intra-Cellular Therapies, a prominent biopharmaceutical company specializing in the development and commercialization of therapeutics for central nervous system disorders, recently made waves in the financial world with its highly successful public offering. However, despite this accomplishment, the company's financial performance and overall ranking have experienced setbacks, leading to uncertainties about its future trajectory. One of the recent hi

[nuovaalta2]

$ITCI #

The financial results release for Intra-Cellular Therapies, Inc. for the quarter and year ended December 31, 2023, will be discussed during a conference call and live webcast at 8:30 a.m. Eastern Time https://csimarket.com/stocks/at_glance.php?code=ITCI&utm_source=dlvr.it&utm_medium=tumblr

[rohans18]

Hoarding Disorder Market Research Report, Growth, Analysis and Forecast 2028

Global Hoarding Disorder Market, By Treatment (Cognitive-Behavioral Therapy (CBT), Antidepressants, Others), Symptoms (Living in unusable spaces due to clutter, Inability to get rid of possessions, Anxiety about needing items in the future, Extreme stress about throwing out items, Distrust of others touching possessions, Uncertainty about where to put things, Withdrawing from friends and family, Others), Dosage (Tablet, Injection, Others), Route of Administration (Oral, Intravenous, Others), End-Users (Clinic, Hospital, Others), Distribution Channel (Hospital Pharmacy, Retail Pharmacy, Online Pharmacy), Country (U.S., Canada, Mexico, Brazil, Argentina, Peru, Rest of South America, Germany, France, U.K., Netherlands, Switzerland, Belgium, Russia, Italy, Spain, Turkey, Hungary, Lithuania, Austria, Ireland, Norway, Poland, Rest of Europe, China, Japan, India, South Korea, Singapore, Malaysia, Australia, Thailand, Indonesia, Philippines, Vietnam, Rest of Asia-Pacific, Saudi Arabia, U.A.E, Egypt, Israel, Kuwait, South Africa, Rest of Middle East and Africa) Industry Trends and Forecast to 2028.

The consistent Hoarding Disorder market report analyzes many points that help businesses to solve the toughest questions in less time. The major topics of this business report are global growth trends, market share by manufacturers, market size by type, market size by application, production by region, consumption by region, company profiles, market forecast, value chain and sales channels analysis, opportunities & challenges, threat and affecting factors. The report gives market definition in the form of market driving factors and market restraints which helps estimating the demand of particular product depending on several aspects. Hoarding Disorder market survey report studies the global market status and forecast, categorizes the global market size, market value & market volume by key players, type, application, and region.

Key Players

The major players covered in the hoarding disorder market report are GlaxoSmithKline plc, Pfizer Inc., AstraZeneca, Johnson & Johnson Private Limited, Bristol-Myers Squibb Company,   Sandoz International GmbH, Apotex Inc., Mylan N.V., H. Lundbeck A/S, Allergan, Sanofi, Merck Sharp & Dohme Corp., Teva Pharmaceutical Industries Ltd., Alkermes, Takeda Pharmaceutical Company Limited., OPKO Health, Inc., Intra-Cellular Therapies Inc., Janssen Pharmaceuticals, Inc., Lupin, Novartis AG, Bausch Health Companies Inc., Eli Lilly and Company, Sumitomo Dainippon Pharma Co., Ltd., AbbVie Inc., and Dr. Reddy’s Laboratories Ltd., among other domestic and global players.  Market share data is available for Global, North America, Europe, Asia-Pacific (APAC), Middle East and Africa (MEA) and South America separately. DBMR analysts understand competitive strengths and provide competitive analysis for each competitor separately.

 Browse More Info @ https://www.databridgemarketresearch.com/reports/global-hoarding-disorder-market

One of the principal objectives of a high-ranking Hoarding Disorder industry report is to analyze and study the global sales, value, status, and forecast. The market report also analyzes the global and key regions market potential and advantage, opportunity and challenge, restraints and risks. The report assists to define, describe and forecast the market by type, application and region. It estimates the region that is foretold to create the most number of opportunities in the global Hoarding Disorder market. This market research report comprises of estimations of CAGR values which are quite significant and aids businesses to decide upon the investment value over the time period. An insightful Hoarding Disorder market report assists clients to stay ahead of the time and competition.

Key questions answered in the report:

Which product segment will grab a lion’s share?

Which regional market will emerge as a frontrunner in coming years?

Which application segment will grow at a robust rate?

Report provides insights on the following pointers:

Market Penetration: Comprehensive information on the product portfolios of the top players in the Hoarding Disorder Market.

Product Development/Innovation: Detailed insights on the upcoming technologies, R&D activities, and product launches in the market.

Competitive Assessment: In-depth assessment of the market strategies, geographic and business segments of the leading players in the market.

Table Of Content

Part 01: Executive Summary

Part 02: Scope Of The Report

Part 03:  Global Market

Part 04: Global Market Sizing

Part 05: Global Market Segmentation By Product

Part 06: Five Forces Analysis

 About Us:

Data Bridge Market Research set forth itself as an unconventional and neoteric Market research and consulting firm with unparalleled level of resilience and integrated approaches. We are determined to unearth the best market opportunities and foster efficient information for your business to thrive in the market

Contact:

Data Bridge Market Research

Tel: +1-888-387-2818

Email: sales@databridgemarketresearch.com

[ustribunenews-blog]

Dropping The 52 Week Low, Intra-Cellular Therapies Inc (ITCI) Closing At $12.39

Dropping The 52 Week Low, Intra-Cellular Therapies Inc (ITCI) Closing At $12.39

Intra-Cellular Therapies Inc (ITCI)

December 18th, 2018 Amidst rising markets Intra-Cellular Therapies Inc finished Tuesday’s trading session down 3.73%, a $0.48 decrease to close on $12.39. As well as the drop in value, Intra-Cellular Therapies Inc hit a new 52 week low of $11.57, breaking the previous low of $12.62 from earlier this month. Intra-Cellular Therapies Inc bounced 10.72% between…

[market-research-future]

Autism Disorder and Treatment Market Insights, Segmentation and Investment To 2027

Autism Disorder and Treatment Market Overview

Autism Spectrum Disorders (ASDs) are developmental illness that causes substantial developmental impairment in social communication and difficulty in fundamental behavior in children. As per MRFR, the autism disorder and treatment market is estimated to gain a 4.37% CAGR during the forecast period.

The global demand for autism disease and treatment is the fastest expanding market. The population's commonness of autism and pervasive developmental disorder (PDD), including Alzheimer's and autism, is on the rise. With an uptick in the number of cases, the market has evolved, increasing the number of technological gadgets and the launch of more healthy strategies for Autistic symptomatic conditions in patients and caregivers. The autism illness and treatment market is being driven by rapid awareness of the ailment, further aiding market expansion in the forecast period.

Request Free Sample Copy at: https://www.marketresearchfuture.com/sample_request/1605

Segmental Analysis

Communication and behavioral therapies, applied behavior analysis (ABA), speech and language therapy, and occupation therapy are the segments based on deployment. Drug therapies, antipsychotic drugs, stimulants, SSRIs, and sleep medication are the segments based on treatment types. Pervasive developmental disorder, Asperger Syndrome, autistic disorder, and disintegrative disorder are several types of Asperger syndrome. The autism disorder and treatment market segment is Europe, Asia-Pacific, North America, and other regional markets.

Detailed Regional Analysis

The autism disease and treatment market is separated into four key regions: America, Europe, Asia Pacific, and the Middle East, and Africa. In the autism disorder and treatment market, America has the most autistic disorders, followed by Europe and other divisions. North Americans have the highest number of instances. Antipsychotics such as Latuda and Namenda will be released soon and are expected to generate money in the US market. The market in the APAC region is also fast increasing, while the markets in the Middle East and Africa are consistently expanding over the projection period.

Competitive Analysis

The market is fueled by global market developments that are being implemented to create a quick return to normalcy. By aligning the resources required to achieve this goal, the majority of stakeholders are judged to accept an increased risk to meet their overall targets. The issues of business stability and reduced cash flows caused by the epidemic are expected to be addressed progressively over the next few years. Overseas portfolio investors are expected to play a critical role in increasing the business interest of new enterprises by innovating the product range currently available in the market. Improved vaccine distribution is expected to accelerate market development as hopeful feelings return to the market. The restoration of demand stability is expected to herald a favorable development phase in the global market in the projected period. The promising impact of macroeconomic reforms is expected to spread throughout the worldwide market during the projection period. The market's emphasis on long-term growth is projected to provide promising development opportunities during the forecast period.

Browse Detailed TOC with COVID-19 Impact Analysis at: https://www.marketresearchfuture.com/reports/autism-disorder-and-treatment-market-1605

The vital companies in the autism disorder and treatment market are Eli Lilly and Company, Teva Pharmaceutical Industries Ltd., Johnson & Johnson Services, Inc., Concern Pharma Private Limited, Bristol-Myers Squibb, and Otsuka Holdings Co., Ltd., Pfizer Inc., Coronis Partners Ltd., Curemark LLC, Allergan, Heptares Therapeutics Limited, Merck & CO Inc., Intra-Cellular Therapies Inc., Saniona AB, and Novartis AG.

Industry Updates:

Nov 2021 An early diagnosis of autism can drastically enhance a child's prospects, according to research whose author calls it a "wake-up call." According to the study, two-thirds of children diagnosed with autism before two-and-a-half make significant improvements, compared to only 23% of children diagnosed later. Within two years of diagnosis, the children were tracked to see if they improved by two or more points on the eight-point scale that rates autism severity.

Browse Related Reports at:

Global Medical Device Reprocessing Market Research Report—Forecast till 2027

Global Surgical Navigation Systems Market Research Report—Forecast till 2027

Global Veterinary Pain Management Market Research Report—Forecast till 2027

About Market Research Future:

At Market Research Future (MRFR), we enable our customers to unravel the complexity of various industries through our Cooked Research Report (CRR), Half-Cooked Research Reports (HCRR), & Consulting Services. MRFR team have supreme objective to provide the optimum quality market research and intelligence services to our clients.

Contact us:

Market Research Future (part of Wantstats Research and Media Private Limited),

99 Hudson Street, 5Th Floor,

New York, New York 10013

United States of America

+1 646 845 9312

Email: sales@marketresearchfuture.com

[mukongs]

Preliminary study on YB1 oncolytic bacterial therapy

New cases of several years of growth, continued high fatality rate, under the increasingly severe global cancer development situation, countless top medical researchers, biological science and technology enterprise and the collective power of global capital within the field of cancer therapy, especially has gradually carry the banner of immunotherapy in the industry market ushered in the outbreak.

According to Transparency Market Research (TMR), the Market size of cancer immunotherapy is expected to grow from us $37.5 billion in 2015 to 124.88 billion in 2024, with a compound annual growth rate (CAGR) of 14.5%.

The TMR market is expected to reach $128.3 billion by 2024, according to a report from KBV, a global research firm. Meticulous Research predicted $152.89 billion; Market Research Engine had the highest estimate at $173 billion.

Although precise data are not available on the future growth of the market, it is certain that the global tumor immunotherapy market is growing, and the expansion of the future cancer population and the development of new oncolytic vector technologies are the main reasons for the expansion of the market.

With the rapid development of new oncolytic vector technology, bacterial therapy has attracted much attention

The cancer immunotherapy market is clearly booming, and there are several emerging therapies in different directions in the segmented areas, including antibodies that block inhibitory immune checkpoint pathways, dendritic cell and engineered T cell cell therapies, and vaccines that trigger antigen-specific immune responses in tumors. And oncolytic vector platforms for presenting tumor-specific cytokines and antibody genes.

Among them, oncolytic virus and oncolytic bacteria as the main new immunotherapy vector technology has attracted more and more attention in the industry. In recent years, the innovation of oncolytic vector technology is developing rapidly. Currently, 4 products of oncolytic virus have been approved and launched in the world, and the competition is fierce, while oncolytic bacteria, as a more cutting-edge breakthrough technology therapy, is also attracting attention in the industry market.

Using microorganisms as a carrier, once the tumor gene therapy is an important field of study, because most of the human body tumor (over 90%) will form a solid tumor, and solid tumor microenvironment has a notable characteristic, that is in the center section of the tumor can form a very special low oxygen zone, the hypoxia zone significantly different from normal group, Therefore, the hypoxic microenvironment of solid tumors becomes an ideal target for tumor targeted therapy.

Soluble tumor bacteria as anaerobic or facultative anaerobic microbe, the tumor area for its lack of oxygen provides an ideal place to live - soluble tumor invasive bacteria are a categories of intracellular bacteria, this kind of reaction between microbes and hosts are are mediated through the type III secretion mechanism, this mechanism can be passed to express effect genes at the same time, the nature of the protein expression of a variety of treatment, therefore, Attenuated tumolytic bacteria is an ideal carrier of therapeutic drugs.

BCG · TUBERCULOSIS

BCG Vaccine is a live Vaccine made from the suspension of attenuated Bovine mycobacterium tuberculosis, which can enhance the activity of macrophages, enhance the ability of macrophages to kill tumor cells, activate T lymphocytes and enhance cellular immunity of the body.

The therapeutic BCG vaccine is the only mature and commercially available bacterial drug product, mainly used for postoperative perfusion of bladder cancer. As an oncolytic bacterium, BCG tuberculosis has been used in the treatment of superficial bladder cancer for more than 30 years, and its clinical effect is remarkable. However, its disadvantages are also obvious, that is, its application scope is relatively limited, it can only be used to treat superficial bladder cancer, and it lacks the means of genetic engineering modification.

(The figure shows the clinical studies of BCG combined with various immune checkpoint antibodies in major pharmaceutical companies around the world)

Bifidobacterium - Clostridium spore

Bifidobacterium is a gram-positive, non-motility, rod-shaped, sometimes bifurcated, strictly anaerobic bacteria genus. Bifidobacterium is one of the important members of the intestinal flora of humans and animals. As an important beneficial microorganism in intestinal tract, bifidobacterium has many important physiological functions such as biological barrier, nutrition, anti-tumor, immune enhancement, gastrointestinal function improvement, anti-aging and so on.

It was found that bifidobacterium has anti-colon cancer effect, which may be through affecting intestinal flora metabolism and enhancing host immune response. Adhesion and degradation of potential carcinogens to prevent intestinal cancer; Change intestinal flora; Produce anti-cancer mutagenic substances; Enhance the immune response of the host; To affect the physiological activity of the host.

In 2020, a university of Chicago study found that adding certain bacteria to the digestive tracts of mice enhanced their immune system's ability to attack tumor cells, and further research found that bifidobacteria was the particular strain that modulated the immune response the most. Dr. Thomas Gajewski, project leader of the study, explained that bifidobacteria may trigger an immune response in humans by interacting with free dendritic cells.

Clostridium is a sporozoa, which is a very unique species in nature. When it enters human or animal body, it often causes muscle and soft tissue infection, intestinal diseases and neurotoxic diseases. A c. POROgenes (ATCC13732) sporosporum powder was also used in clinical studies in the 1970s. This may have been a non-standard clinical trial, which was conducted in humans on five tumor patients after the non-pathogenic clostridium caseinate M55 strain was shown. After intravenous administration of spores of Clostridium butyricum M55, the 3 patients with the largest tumors developed oncolytic but no surrounding tissues or smaller metastases. In one case, a temporary clinical benefit was attributed to oncolytic effects caused by clostridium difficile.

In 1978, another trial was carried out for patients with angioblastoma by intra-carotid injection. One week after the injection, most patients' tumors were completely dissolved, but the glioblastoma turned into a brain abscess, and surgery was performed to prevent rupture and death. The results of these studies indicate that despite the established evidence of safety and colonization following intravenous administration, there is an overall lack of clinical benefit due to tumor regeneration from the outer edges of living cells with good blood vessels.

The advantage of bifidobacteria-Clostridium spore oncolytic bacteria is that they are obligate anaerobe and will not be distributed in normal organs. The disadvantage is that it can only be distributed in very large tumors, and can only target the necrotic area of the tumor, oxygen concentration is less than 0.01%, there are no living tumor cells in this area, so the therapeutic effect is limited.

listeria

Listeria is a Gram-positive bacterium, belonging to firmicutes. It is mainly food-borne and is one of the most deadly food-borne pathogens. Listeria has also been widely used in the research of bacterial vectors in the field of cancer treatment. Johnson & Johnson and its subsidiary Aduro Biotech used Listeria as an antigen vector to advance clinical trials. In 2014, Johnson & Johnson and Aduro's listeria project CRS-207 combined with GVAX in the treatment of pancreatic cancer was recognized as a breakthrough therapy by the FDA of the United States, and the trial entered the clinical phase II. However, the follow-up results were not satisfactory, and Aduro finally gave up the promotion plan of THE CRS-207 project.

In January 2019, the FDA halted the enrollment of patients in a phase 3 clinical trial of Advaxis inc. 's AXAL program in Princeton, New Jersey. Advaxis is a late-stage biotech company focused on the discovery, development and commercialization of immunotherapy products, including AXAL, which effectively eliminates human cells infected with HPV. The drug is a bacterial therapy developed by Advaxis' exclusive Listeria immunotherapy technology platform.

In this technique, listeria is introduced into a foreign gene via a plasmid vector to express a fusion protein consisting of an active fragment of the toxin protein LLO and the target antigen E7 protein. The LLO protein derived from Listeria ensures the survival of the bacteria after phagocytosis by antigen-presenting cells (APC) in the human body. AXAL, which has been shown in early trials and preclinical studies, stimulates the body's immune system to recognize the presence of tumor cells and reduce their natural defenses, which in turn encourages the body's own killer T cells to attack the tumor cells.

The FDA's decision to halt Advaxis's bacterial treatment for cervical cancer is the latest setback in the development of a bacterial treatment for listeria. In terms of the strain itself, the advantage of Listeria is that it can carry tumor antigens, but there are two disadvantages: first, many tumor antigens are not obvious, so specific antibodies for tumor treatment is limited; Second, the strain will be distributed in normal organs, affecting human health.

salmonella

Among various kinds of bacteria types, most of the research on salmonella typhimurium, at least more than 10 of genetically engineered based on salmonella typhimurium attenuated strain in preclinical studies, port of medicine soluble tumor biological pharmaceutical co., LTD. The core technology of product YB1 was the first to use synthetic biology technology designed specifically for cancer treatment of salmonella strains.

Though of facultative anaerobic bacteria such as salmonella attenuated abound, but the starting point of past a lot of research is induced by chemical drugs, such as making attenuated bacteria or do some nutrition metabolic gene mutations, while it is possible to realize the characteristics of the tumor target, but can only form a certain scale, such as tumor, liver = 1000: Although the ratio of 1 can reach 10^9CFU/g tissue in the tumor, it can also reach 10^6CFU/g in the liver, which will cause safety risks, and also cause the dose of bacteria can not be injected too much.

From the experimental data, the oncolytic salmonella vector YB1 of Hong Kong medicine has obvious advantages after modification: in vivo, if YB1 is in the tumor region, due to the oxygen content of YB1 is less than 0.5%, its tumor aggregation ability will not be affected, can reach 10^9CFU/g tissue; However, if YB1 is in an environment where oxygen concentration is higher than 0.5%, such as liver and other tissues, YB1 will be cleared quickly, thus achieving great tumor targeting and safety.

As Hong Kong medicine soluble tumor core technology products, with genetic programming modification of salmonella YB1 is currently the world's first successful development of soluble tumor bacteria carrier, and has been applied to pet primary cancer treatment, clinical effect is very outstanding, there is risk of malignant tumor after cured by YB1 pet dog has achieved more than 4 years cancer-free survival.

summary

Throughout the development of bacteria in the field of global cancer immunotherapy therapy, with different types of bacteria as the carrier to develop bacteria soluble tumor therapy, the curative effect in the experiment is endless also and same, some hit stagnate, some effect is prominent, full of unknown laboratory platform in the world, the development process of soluble tumor therapy bacteria to humans bring a surprise, There were regrets, but more than that, there was hope.

[fmarkets]

Intra Cellular Therapies Inc Reports a Loss of $-0.29 per Share in Q4 of 2023 https://csimarket.com/stocks/news.php?code=ITCI&date=2024-02-22170209&utm_source=dlvr.it&utm_medium=tumblr

[preranajoshi1096]

Depression Drugs Market - Global Industry Analysis, Size, Share, Growth, Trends, and Forecast 2021 – 2027

Global Depression Drugs Market: Global Size, Trends, Competitive, Historical & Forecast Analysis, 2019-2025. Growing in geriatric population, increase in the knowledge about depression, rising number of generic drug market and declining side effects of drugs are projected to boost the growth of Global Depression Drugs Market.

Scope of Global Depression Drugs Market Reports –

 As per WHO, depression is a common mental disorder includes brain that contributes significantly to the global burden of disease. Depression is a serious mood disorder which causes a tenacious feeling of sadness and loss of interest therefore affecting daily routine activities such as sleeping, walking, talking, thinking and eating.Depression is a mental health issue. It is a condition that begins more often in initialstages of adulthood. Also it is more commonly observe in women. Though, anyone at any age may get suffer from depression.Depression affects the brain so drugs that work in the brain called ‘Antidepressant Drugs’. General antidepressants candecrease symptoms, but there are many other options to reduce the depression.

Get Sample Copy for Depression Drugs Market Report for 2021 @ https://brandessenceresearch.com/requestSample/PostId/47

Each drug used to treat depression by balancing certain chemicals in brain known as‘Neurotransmitters’. Signs and symptoms of depression differ from individual to individualon the basis of risk factors, individual thinking and lifestyle. It includes sadness, irritability, loss of attention in daily routine activities, feelings of pessimism, guilt, social withdrawal, fatigue, insomnia, loss of appetite, headache, cramps, digestive problems, weight loss or gain, restlessness and suicide attempts.Also, alcoholism and drug abuse may be the signs of depression. Likewise there are different types of depression which has distinctive characteristics such as persistent depressive disorder, perinatal depression disorder, psychotic depression, Seasonal affective disorder and bipolar depression. Depression is also classified based on its severity as mild, moderate and severe. An individual with severe depression can have suicidal thoughts and behaviors. According to 2012estimation by the WHO around 3,000 suicides take place per day, resulting in more than a million deaths each year. Depression can be recurringand can be severely debilitating. Patients with mild depression can be treated with medications but in moderate or severe depressioncases, the patient needs both medication and professional psychotherapy in the form of counseling.

Key Players– Global Depression Drugs Market reports cover prominent players like Otsuka Pharmaceutical Co., Ltd., Eli Lilly and Company, Pfizer Inc., AstraZeneca, Allergan USA, Inc., Novartis AG, GlaxoSmithKline, Takeda Pharmaceutical Company Ltd, Sebela Pharmaceutical Inc., Johnson & Johnson, Merck & Co., SK Biopharmaceuticals, Forest Laboratories, Naurex, Actavis, Bristol-Myers Squibb, Intellipharmaceutics, Lundbeck, Allergan, NHU Group,Shionogi, Kanghong Pharma, HUAHAI,Addex Therapeutics,  Alkermes, Cerecor, Dart NeuroScience,  Dr. Reddy’s Laboratories, Edgemont Pharmaceuticals, Euthymics, Fabre Kramer, Gedeon Richter, Intra-Cellular Therapies,Janssen Pharmaceuticals, Lupin, Luye Pharma, MSI Methylation Sciences, Opko Health, Shire, Somerset Pharmaceuticals, Sun Pharmaceutical, Sunovion Pharmaceuticals, Torrent Pharmaceuticals and Valeant Pharmaceuticals.

 Market Dynamics –

Increasing geriatric population globally, growing efficacy and decreasing side effectsofantidepressant drugs are the main factors that drive the Global Depression Drug Market. Also, various government initiatives in increasing awareness on depression, elevating generic drug market, are boosting theGlobal Depression Drugs Market. People transfer from rural to urban areas for job, education, etc. and their suddenly changing lifestyle is one of the key factors driving the growth of Global Depression Drugs Market. Though, lack of awareness among persons regarding depression& its growingoccurrence and threat of expiry of patents would decline the demand for Antidepressant drugs in forecast period.However, non-availability of well-developed healthcare facilities especially in rural and remote areas may decline the growth of the Global Depression Drugs Market. Regional Analysis –

Geographically, North America accounted for the largest market share of around 37.20% in 2016; due to high patient awareness levels regarding availability of various antidepressant drugs for increasing healthcare expenditure and relatively larger number of Research & Development affecting to drug manufacturing and marketing etc. These factors contribute for significant revenue generation from the region. Europe have the second largest share of the Global Depression Drugs Market in 2017, which can be recognized to the increase in research and development activities on depression drugs in the region. Asia-Pacific is to attain the fastest CAGR during the forecast period, owed to increased demand from developing countries such as China, Japan, and Australia. An initiative by the local government to reach self-sufficiency in the manufacturing of Antidepressant drugs and increasing awareness amongst consumers regarding benefits of Antidepressant drug is also likely to boost the growth of Global Depression Drugs Market in the region.

Key Benefits for Market Reports –

Global     Depression Drugs Marketreport covers in depth historical and forecast     analysis.

Global     Depression Drugs Marketresearch report provides detail information about     Market Introduction, Market Summary, Global market Revenue (Revenue USD),     Global market sale (K Units), Global market Drivers, Market Restraints,     Market opportunities, Competitive Analysis, Regional and Country Level.

Global     Depression Drugs Marketreport helps to identify opportunities in market     place.

Global     Depression Drugs Marketreport covers extensive analysis of emerging trends     and competitive landscape.

Depression Drugs Market Segmentation–

 By Drug type Analysis - Tricyclic Antidepressants, Serotonin-Norepinephrine Inhibitors, Atypical Antipsychotics, Selective Serotonin Reuptake Inhibitors, Benzodiazepines, Tetracyclic Antidepressants, Monoamine Oxidase Inhibitors, Other

By Disease Type Analysis  Major Depressive Disorder - Schizophrenia, Bipolar I Disorder, Selective Serotonin Reuptake Inhibitor Induced Disorder, Other

By Distribution channel Analysis - Hospital pharmacies, Retail pharmacies, Online pharmacies, Clinics, Research centres, Other

By Regional & Country Analysis

North America, US, Mexico, Chily, Canada, Europe, UK, France, Germany, Italy, Asia Pacific, China, South Korea, Japan, India, Southeast Asia, Latin America, Brazil, The Middle East and Africa, GCC, Africa, Rest of Middle East and Africa

Depression Drugs Market Key Players:

Otsuka     Pharmaceutical Co., Ltd.

Eli     Lilly and Company

Pfizer     Inc.

AstraZeneca

Allergan     USA, Inc.

Novartis     AG

GlaxoSmithKline

Takeda     Pharmaceutical Company Ltd

Sebela     Pharmaceutical Inc.

Johnson     & Johnson

Merck     & Co.

SK     Biopharmaceuticals

Forest     Laboratories

Naurex

Actavis

Bristol-Myers     Squibb

Intellipharmaceutics

Lundbeck

Allergan

NHU     Group

Shionogi

Kanghong     Pharma

HUAHAI

Addex     Therapeutics

[your-dietician]

FDA Clears Sorrento Phase 2 Trial Of Non-Opioid Product Candidate Resiniferatoxin (RTX) For Treatment of the Knee Pain in Osteoarthritis (OA) Patients

New Post has been published on https://depression-md.com/fda-clears-sorrento-phase-2-trial-of-non-opioid-product-candidate-resiniferatoxin-rtx-for-treatment-of-the-knee-pain-in-osteoarthritis-oa-patients/

FDA Clears Sorrento Phase 2 Trial Of Non-Opioid Product Candidate Resiniferatoxin (RTX) For Treatment of the Knee Pain in Osteoarthritis (OA) Patients

Phase 2 trial of RTX for OA pain to proceed following FDA clearance.

Phase 1b data demonstrated RTX safety for a single intra-articular administration without dose limiting toxicity (DLT) at any doses tested up to 30 ug.

Phase 1b data demonstrated significant efficacy supporting RTX as an ideal candidate for long-term control of refractory OA pain: significant pain relief observed in patients with advanced OA disease (Kellgren-Lawrence grade 3/4) and sustained pain relief last beyond 6 months.

Sorrento believes RTX has the potential to become a key therapeutic in a market segment estimated to continue to grow and exceed $10B by 20251

SAN DIEGO, July 06, 2021 (GLOBE NEWSWIRE) — Sorrento Therapeutics, Inc. (NASDAQ: SRNE, “Sorrento”) announced today that the company has received FDA clearance to proceed with a Phase 2 clinical study of RTX for treating moderate-to-severe osteoarthritis of the knee pain (OAK).

The phase 2 trial, a multi-center, double blind, placebo- and active-controlled study, will assess the efficacy and safety of several dose groups of RTX to manage pain in patients with moderate-to-severe osteoarthritis of the knee pain (OAK) (clinicaltrials.gov: NCT04885972). Given the durability of OA pain relief response to RTX demonstrated thus far, Sorrento has decided to include an active comparator (injectable corticosteroid) in the current trial protocol. Superiority data potentially generated by RTX against a widely used approved drug could be supportive for accelerated international registrations (Europe) and is required for pricing purposes in Europe.

This Phase 2 study follows the analysis of the significant observations from the Phase 1b trial results (NCT03542838) of RTX Day 84 patient data which completed the one year following up of last patient visit in February 2021. This Phase 1b study was a double-blinded, placebo-controlled ascending dose study in 94 patients and included an open-label expansion cohort to assess the long-term safety and preliminary efficacy of a single intra-articular administration of RTX or saline control (as placebo group) for the treatment of moderate-to-severe pain due to osteoarthritis of the knee. The magnitude of the difference in the treatment effect (RTX versus saline control) at 12 weeks exceeded what is traditionally considered sufficient to support regulatory approval based on greater than 2 points reduction in WOMAC A1 10-point scale question “pain at walking on flat surface” compared to placebo. RTX met this requirement in this study.

Story continues

The Phase 1b study was designed to follow patients to day 84 (primary endpoint). Patients were also given the option to be followed for up to a year. Pain relief appeared to be very consistent among patients responding to the initial treatment, with a large proportion of the patients followed past Day 84 showing pain relief sustained beyond all time points assessed through one year follow-up. Fast relief (starting within days, with optimal pain relief level achieved within weeks) and durability of the effect (past 84 days) confirm the clinical potential of the RTX drug for long-term control of pain associated with osteoarthritis of the knee.

The RTX clinical development program continues, with Phase 2 and 3 clinical trials planned in larger patient populations. The first Phase 2 trial will focus on identifying the recommended Phase 3 dose.

_______________ 1 Osteoarthritis Market Size, Share, Value, And Competitive Landscape 2021-2026 – MarketWatch

About RTX

A thousand times “hotter” than pure capsaicin (16 billion Scoville units versus 16M), and with a high affinity for afferent sensory pain nerves, RTX binds to TRPV1 receptors present and selectively ablates the nerve endings responsible for pain signals experienced by patients2. Delivered peripherally (into the joint space) the transient nerve ending ablation effect can have profound clinical benefits lasting for months to years (as shown in canine studies3).

PTVA-OA-001 was a multicenter, placebo-controlled Phase 1b study to assess the safety and define the maximally tolerated dose of RTX administered in the knee joint in patients with moderate to severe pain associated with osteoarthritis of the knee. The study was a dose-escalation trial in which cohorts of patients receive increasing doses of RTX until the maximum tolerated dose (MTD) was achieved. The primary objective of the study was to evaluate the safety of RTX and identify the recommended Phase 3 dose. The secondary objective was to assess the preliminary efficacy of RTX measured by assessing changes in the intensity of pain using the A1 score from the WOMAC, a widely used proprietary validated pain questionnaire.

The osteoarthritis treatment market and in particular the Knee Osteoarthritis and injectable markets have historically seen healthy growth and are expected to continue the trend as populations age and present excessive weight. Multiple sources estimate the 2020 market to be around 50M patients and $7B.

More information on this completed trial can be found at www.clinicaltrials.gov (NCT03542838).

_______________ 2 https://www.ncbi.nlm.nih.gov/pmc/articles/PMC398431/ 3 Sorrento Therapeutics (Ark Animal Health) internal data (on file)

About Sorrento Therapeutics, Inc.

Sorrento is a clinical stage, antibody-centric, biopharmaceutical company developing new therapies to treat cancers and COVID-19. Sorrento’s multimodal, multipronged approach to fighting cancer is made possible by its extensive immuno-oncology platforms, including key assets such as fully human antibodies (“G-MAB™ library”), clinical stage immuno-cellular therapies (“CAR-T”, “DAR-T™”), antibody-drug conjugates (“ADCs”), and clinical stage oncolytic virus (“Seprehvir™”). Sorrento is also developing potential antiviral therapies and vaccines against coronaviruses, including COVIGUARD™, COVI-AMG™, COVISHIELD™, Gene-MAb™, COVI-MSC™ and COVIDROPS™; and diagnostic test solutions, including COVITRACK™, COVISTIX™ and COVITRACE™.

Sorrento’s commitment to life-enhancing therapies for patients is also demonstrated by our effort to advance a first-in-class (TRPV1 agonist) non-opioid pain management small molecule, resiniferatoxin (“RTX”), and SP-102 (10 mg, dexamethasone sodium phosphate viscous gel) (SEMDEXA™), a novel, viscous gel formulation of a widely used corticosteroid for epidural injections to treat lumbosacral radicular pain, or sciatica, and to commercialize ZTlido® (lidocaine topical system) 1.8% for the treatment of post-herpetic neuralgia. RTX has completed a Phase IB trial for intractable pain associated with cancer and a Phase 1B trial in osteoarthritis patients. SEMDEXA is in a pivotal Phase 3 trial for the treatment of lumbosacral radicular pain, or sciatica. ZTlido® was approved by the FDA on February 28, 2018.

For more information visit www.sorrentotherapeutics.com.

Forward-Looking Statements

This press release and any statements made for and during any presentation or meeting contain forward-looking statements related to Sorrento Therapeutics, Inc., under the safe harbor provisions of Section 21E of the Private Securities Litigation Reform Act of 1995 and subject to risks and uncertainties that could cause actual results to differ materially from those projected. Forward-looking statements include statements regarding the expectations for Sorrento’s and its subsidiaries’ technologies and product candidates, including, but not limited to, resiniferatoxin (RTX), the clinical potential of RTX, including the potential for RTX to address long-term control of pain associated with osteoarthritis of the knee, RTX’s potential to become a major therapeutic in the knee osteoarthritis and injectable markets, timing for commencing additional Phase 2 and 3 clinical trials for RTX, timing for completion and submission of a request to proceed with any Phase 3 trial for RTX, the possibility of proceeding to a Phase 3 trial, and the possibility of obtaining accelerated international registration for RTX in Europe. Risks and uncertainties that could cause our actual results to differ materially and adversely from those expressed in our forward-looking statements, include, but are not limited to: risks related to Sorrento’s technologies and prospects, including, but not limited to risks related to seeking regulatory approval for RTX; clinical development risks, including risks in the progress, timing, cost, and results of clinical trials and product development programs; risk of difficulties or delays in obtaining regulatory approvals; risks that clinical study results may not meet any or all endpoints of a clinical study and that any data generated from such studies may not support a regulatory submission or approval; risks that prior test, study and trial results may not be replicated in future studies and trials; risks of manufacturing and supplying drug product; risks related to leveraging the expertise of its employees, subsidiaries, affiliates and partners to assist Sorrento in the execution of its therapeutic antibody product candidate strategies; risks related to the global impact of COVID-19; and other risks that are described in Sorrento’s most recent periodic reports filed with the Securities and Exchange Commission, including Sorrento’s Annual Report on Form 10-K for the year ended December 31, 2020, and subsequent Quarterly Reports on Form 10-Q filed with the Securities and Exchange Commission, including the risk factors set forth in those filings. Investors are cautioned not to place undue reliance on these forward-looking statements, which speak only as of the date of this release and we undertake no obligation to update any forward-looking statement in this press release except as required by law.

Media and Investor Relations Contact Alexis Nahama, DVM (SVP Corporate Development) Email: mediarelations@sorrentotherapeutics.com

Sorrento® and the Sorrento logo are registered trademarks of Sorrento Therapeutics, Inc.

G-MAB™, DAR-T™, SOFUSA™, COVIGUARD™, COVI-AMG™, COVISHIELD™, Gene-MAb™, COVIDROPS™, COVI-MSC™, COVITRACK™, COVITRACE™ and COVISTIX™ are trademarks of Sorrento Therapeutics, Inc.

SEMDEXA™ is a trademark of Semnur Pharmaceuticals, Inc.

ZTlido® is a registered trademark owned by Scilex Pharmaceuticals Inc.

All other trademarks are the property of their respective owners.

©2021 Sorrento Therapeutics, Inc. All Rights Reserved.

Source link

[ustribunenews-blog]

Lowering The 52 Week Low, Intra-Cellular Therapies Inc (Nasdaq:ITCI) Finishing At $13.53

Lowering The 52 Week Low, Intra-Cellular Therapies Inc (Nasdaq:ITCI) Finishing At $13.53

Intra-Cellular Therapies Inc (Nasdaq:ITCI)

December 6th, 2018 Intra-Cellular Therapies Inc fell $0.29 Thursday, a 2.10% drop, closing at $13.53. As well as the drop in value, Intra-Cellular Therapies Inc hit a new 52 week low of $13.29, breaking the previous low of $13.78 from earlier this month. Be aware that the Piotroski Score1 is calculated to be 2, which is very low as the scale goes from…

[athiranair23]

Bipolar Disorders Treatment Market Analysis (2020-2027)

Bipolar disorder is a lifelong disease, which can be managed with proper medication. The medications used to manage bipolar disorder symptoms include mood stabilizers and atypical antipsychotics. Mood stabilizers such as lithium and other drugs are used for the treatment of bipolar disorders by suppressing mood swings such as mania and depression. Cariprazine is an atypical antipsychotic drug indicated for the treatment of depressive episodes associated with bipolar I disorder in adults. Antidepressant medications are also prescribed to treat depressive episodes in bipolar disorder. Antidepressants combined with mood stabilizers are indicated to prevent triggering of maniac episode in patients with bipolar disorder.

Market Dynamics

The increasing adoption of inorganic growth strategies such as mergers, agreements, and collaborations by key players operating in the market are expected to propel the market growth over the forecast period. For instance, in July 2019, Gedeon Richter plc, entered into an exclusive license agreement with Hikma Pharmaceuticals Plc. to commercialize cariprazine, a novel antipsychotic drug, in certain Middle East and North African or MENA markets. Moreover, earlier in August 2016, Gedeon RichterPlc. and Recordati signed an exclusive license agreement to commercialize cariprazine, a novel atypical antipsychotic drug in Western Europe, Algeria, and Tunisia.

Key features of the study:

·         This report provides in-depth analysis of the global bipolar disorder treatment market, and provides market size (US$ Mn) and compound annual growth rate (CAGR%) for the forecast period (2019–2027), considering 2019 as the base year

·         It elucidates potential revenue opportunities across different segments and explains attractive investment proposition matrices for this market

·         This study also provides key insights about market drivers, restraints, opportunities, new product launches or approval, market trends, regional outlook, and competitive strategies adopted by key players

·         It profiles key players in the global bipolar disorder treatment market based on the following parameters – company overview, financial performance, Device portfolio, market presence, distribution strategies, key developments, strategies, and future plans

·         Key companies covered as a part of this study include Takeda Pharmaceutical Company Limited, Pfizer, Inc., Allergan plc, Otsuka Holdings Co. Ltd., Johnson & Johnson, Eli Lilly and Company, GlaxoSmithKline plc, AstraZeneca Plc, Novartis International AG, AbbVie Inc., H. Lundbeck A/S, Minerva Neurosciences, Sumitomo Dainippon Pharma Co., Ltd., Intra-Cellular Therapies Inc., Gedeon Richter Plc., and Indivior PLC

·         Insights from this report would allow marketers and the management authorities of the companies to make informed decisions regarding their future device launches, drug class up-gradation, market expansion, and marketing tactics

·         The global bipolar disorder treatment market report caters to various stakeholders in this industry including investors, suppliers, device manufacturers, distributors, new entrants, and financial analysts

·         Stakeholders would have ease in decision-making through various strategy matrices used in analyzing the global bipolar disorder treatment market

Detailed Segmentation:

·         Global Bipolar Disorder Treatment Market, By Drug Class:

o    Antipsychotics

o    Antidepressants

o    Mood Stabilizers

o    Anti-anxiety Drugs and Others

·         Global Bipolar Disorder Treatment Market, By Distribution Channel:

o    Hospital Pharmacies

o    Retail Pharmacies

o    Online Pharmacies

·         Global Bipolar Disorder Treatment Market, By Region:

o    North America

§  By Drug Class:

§  Antipsychotics

§  Antidepressants

§  Mood Stabilizers

§  Anti-anxiety Drugs and Others

§  By Distribution Channel:

§  Hospital Pharmacies

§  Retail Pharmacies

§  Online Pharmacies

§  By Country:

§  U.S.

§  Canada

o    Latin America

§  By Drug Class:

§  Antipsychotics

§  Antidepressants

§  Mood Stabilizers

§  Anti-anxiety Drugs and Others

§  By Distribution Channel:

§  Hospital Pharmacies

§  Retail Pharmacies

§  Online Pharmacies

§  By Country:

§  Brazil

§  Mexico

§  Argentina

§  Rest of Latin America

o    Europe

§  By Drug Class:

§  Antipsychotics

§  Antidepressants

§  Mood Stabilizers

§  Anti-anxiety Drugs and Others

§  By Distribution Channel:

§  Hospital Pharmacies

§  Retail Pharmacies

§  Online Pharmacies

§  By Country:

§  Germany

§  U.K.

§  France

§  Italy

§  Spain

§  Russia

§  Rest of Europe

o    Asia Pacific

§  By Drug Class:

§  Antipsychotics

§  Antidepressants

§  Mood Stabilizers

§  Anti-anxiety Drugs and Others

§  By Distribution Channel:

§  Hospital Pharmacies

§  Retail Pharmacies

§  Online Pharmacies

§  By Country:

§  China

§  India

§  Japan

§  Australia

§  South Korea

§  ASEAN

§  Rest of Asia Pacific

o    Middle East

§  By Drug Class:

§  Antipsychotics

§  Antidepressants

§  Mood Stabilizers

§  Anti-anxiety Drugs and Others

§  By Distribution Channel:

§  Hospital Pharmacies

§  Retail Pharmacies

§  Online Pharmacies

§  By Country:

§  GCC

§  Israel

§  Rest of Middle East

o    Africa

§  By Drug Class:

§  Antipsychotics

§  Antidepressants

§  Mood Stabilizers

§  Anti-anxiety Drugs and Others

§  By Distribution Channel:

§  Hospital Pharmacies

§  Retail Pharmacies

§  Online Pharmacies

§  By Country/Region:

§  South Africa

§  Central Africa

§  North Africa

·         Company Profiles

o    Takeda Pharmaceutical Company Limited*

§  Company Overview

§  Material Portfolio

§  Financial Performance

§  Key Highlights

§  Market Strategies

o    Pfizer, Inc.

o    Allergan plc

o    Otsuka Holdings Co. Ltd.

o    Johnson & Johnson

o    Eli Lilly and Company

o    GlaxoSmithKline plc

o    AstraZeneca Plc

o    Novartis International AG

o    AbbVie Inc.

o    Lundbeck A/S

o    Minerva Neurosciences

o    Sumitomo Dainippon Pharma Co., Ltd.

o    Intra-Cellular Therapies Inc.

o    Gedeon Richter Plc.

o    Indivior PLC

“*” marked represents similar segmentation in other categories in the respective section.

   Request sample copy here :  

https://www.coherentmarketinsights.com/insight/request-sample/2605

Request PDF brochure here:        

https://www.coherentmarketinsights.com/insight/request-pdf/2605

Click here to buy: https://www.coherentmarketinsights.com/insight/buy-now/2605

CMI Services: https://www.coherentmarketinsights.com/services

About Us:

Coherent Market Insights is a global market intelligence and consulting organization focused on assisting our plethora of clients achieve transformational growth by helping them make critical business decisions.

What we provide:

·        Customized Market Research Services

·        Industry Analysis Services

·        Business Consulting Services

·        Market Intelligence Services

·        Long term Engagement Model

·        Country Specific Analysis

Contact Us:   

Mr. Shah

Coherent Market Insights Pvt. Ltd.

Address: 1001 4th ave, #3200 Seattle, WA 98154, U.S.

Phone: +1-206-701-6702

Email : sales@coherentmarketinsights.com

 Reference/Source: https://www.coherentmarketinsights.com/market-insight/bipolar-disorders-treatment-market-2605

[kunalcmi]

ANTIMANIA DRUGS MARKET ANALYSIS(2020-2027)

Antimania drugs are used in the treatment of bipolar disorder, a type of mood disorder also called as manic depression or manic-depressive illness, where patient’s mood fluctuate from feeling depressed to feeling super charged or manic.

The most widely used medication for the treatment of acute mania include lithium, valproate & carbamazepine (antipsychotics), ziprasidone, aripiprazole & clozapine (atypical antipsychotics), and lorazepam (benzodiazepine). Additionally, for the treatment of prophylaxis of bipolar mood disorder, lithium carbonate and lithium citrate are mostly used. Carbamazepine reduces transmission of the nerve impulse in the brain, which in turn reduces severity of manic episodes. Moreover, carbamazepine can be used as alternative to lithium salts, when patients fails to respond to lithium. Furthermore, sometimes carbamazepine are used with the combination of lithium, when there is need of rapid control of acute mania.

 Global Antimania Drugs Market Drivers  

The global antimania drugs market is expected to witness significant growth over the forecast period, owing to growing prevalence of bipolar disorder, globally. For instance, according to the World Health Organization (WHO) 2019 report, around 45 million people get affected by bipolar disorder globally.

Moreover, cost effectiveness of drugs for the treatment of bipolar disorder is another factor that is expected to drive the global antimania drugs market growth over the forecast period. For instance, cost of olanzapine is US$ 153, while cost of lithium is US$ 16 per month.

Furthermore, increasing number of clinical trials of drug for the treatment of bipolar depression, which is expected to propel the global antimania drugs market growth over the forecast period. For instance, in July 2018, Lumateperone received positive results from the Phase 3 clinical trial (Study 401 and Study 404) for the treatment of bipolar depression, announced by Intra-Cellular Therapies, Inc. In both the trials (Study 401 and Study 404), Lumateperone was found safer and tolerable by patients.

 Moreover, in October 2019, Psychiatry Consortium, which is a strategic collaboration of leading medical research charities and pharmaceutical companies to accelerate innovative drug discovery in psychiatric diseases, had announced to launch a novel drug project to address people with mental health conditions such as bipolar disorder, depression and other mental disorders.

Psychiatry Consortium is a pioneering collaboration between the pharmaceutical companies, healthcare companies as well as leading medical charities. Therefore, increasing initiatives by companies to support the novel drug project, which in turn, is expected to increase the launch of new drugs for treatment of patients with mental health condition such as bipolar disorder and hence drives the global antimania drugs market growth.

 Global Antimania Drugs Market Restraints

However, side effects associated with lithium for the treatment of bipolar disorder is one of the major factors that is expected to restrain the global antimania drugs market growth over the forecast period. For instance, if patient takes overdose of lithium, it causes anorexia.  Moreover, prolong use of lithium can damage body’s ability to respond properly to the hormone vasopressin and can result into diabetes insipidus.

 Request Sample Free Copy of Report here: https://www.coherentmarketinsights.com/insight/request-sample/4143

Download PDF Brochure: https://www.coherentmarketinsights.com/insight/request-pdf/4143

 Global Antimania Drugs Market Regional Analysis

North America is expected to hold the highest market share in global antimania drugs market, owing to factors such as increasing technological advancements such as BiAffect app by�� University of Illinois, Chicago that helps to facilitate accurate detection of a patient’s mood and mental state. For instance, in 2018, the University of Illinois, Chicago (UIC) launched BiAffect app, which helps to track manic disorder and depressive mood in the patient with biopolar disorder. Moreover, BiAffect app predict mood episodes by analyzing the stroke dynamics such as error and typing speed of the patient. Therefore, launch of BiAffect app is expected to drive demand of antimania drugs for the treatment of bipolar disorder.

Moreover, increasing approvals of drug such as Vraylar by U.S Food and Drug administration (FDA) for the treatment of bipolar disorder is another factor that is expected to boost global antimania drugs market growth. For instance, in May 2019, Allergan plc and Gedeon Richter Plc announced to receive the approval from the U.S Food Drug Administration for expanded use of Vraylar (cariprazine) in the treatment of depressive episodes associated with bipolar I disorder (bipolar depression) in adults.

 Among regions, Europe is expected to hold the second highest market share in global antimania drug market, owing to increasing launches of new drugs for the treatment of bipolar disorder in Europe. For instance, in September 2019, LATUDA, an atypical antipsychotic agent was launched by Sumitomo Dainippon Pharma Co., Ltd., in China. LATUDA is used for the treatment bipolar depression. Additionally, the National Medical Products Administration (NMPA) has granted import drug license for LATUDA drug in China.

 Global Antimania Drugs Market Key Players

Key players operating in the global antimania market are Eli Lilly and Company, Sumitomo Dainippon Pharma Co., Ltd, Allergan plc, Xian Janssen Pharmaceutical Ltd, Pfizer Inc., Otsuka Pharmaceutical, Taro Pharmaceutical Industries Ltd, Apotex Inc., Teva Pharmaceutical Industries Ltd, and Torrent Pharmaceutical Ltd.

 Market Taxonomy:

On the basis of drug, the global antimania drugs market is segmented into:

Lithium Salts

Carbamazepine

Valproic Acid

Lamotrigine

Olanzapine

Others

On the basis of distribution channel, the global antimania drugs market is segmented into:

Hospital Pharmacies

Retail Pharmacies

Online Pharmacies

On the basis of region, the global antimania drugs market is segmented into:

North America

Latin America

Europe

Middle East

Asia Pacific

Africa

About Us:

Coherent Market Insights is a global market intelligence and consulting organization focused on assisting our plethora of clients achieve transformational growth by helping them make critical business decisions.

 What we provide:

Customized Market Research Services

Industry Analysis Services

Business Consulting Services

Market Intelligence Services

Long term Engagement Model

Country Specific Analysis

Contact Us:

Mr. Shah

Coherent Market Insights Pvt. Ltd.

Address: 1001 4th ave, #3200 Seattle, WA 98154, U.S.

Phone: +1-206-701-6702

Email: sales@coherentmarketinsights.com

Source: https://www.coherentmarketinsights.com/ongoing-insight/antimania-drugs-market-4143

[fmarkets]

Robust Revenue and Reduced Losses Propel Intra Cellular Therapies Inc to Stand Out in Major Pharmaceutical Preparations Industry https://csimarket.com/stocks/news.php?code=ITCI&date=2023-11-02175041&utm_source=dlvr.it&utm_medium=tumblr